(509) 228-1000 WA
(208) 754-3100 ID

Jessica Hellyer, MD

Share

back to doctor information

Specialty

Medical Oncology and Hematology

Location:

SOUTH SPOKANE

Additional Areas of Expertise:

Lung Cancer

Dr. Hellyer graduated magna cum laude from Colorado College with a degree in biochemistry. She went on to attend medical school at University of Colorado where she graduated with honors as a member of the Alpha Omega Alpha honor society. She completed internal medicine residency and subspecialty training in medical oncology at Stanford Hospital in Palo Alto.
 
During her medical oncology training Dr. Hellyer developed expertise in the treatment of lung cancer, including non-small cell and small cell lung cancers, mesothelioma, and thymic malignancies. She believes in tailoring treatment to each patient and using genetic data from patients’ tumors to help guide treatment. Dr. Hellyer is passionate about improving the lives of patients and advancing the field of oncology through clinical research. She has conducted extensive research into the molecular drivers of lung cancer and the ways in which this information can be used to improve and personalize treatment for patients living with lung cancer.
 
In her free time, Dr. Hellyer enjoys spending time with her husband and family and exploring the Inland Northwest.

Clinical Trials

TRIAL NUMBER - NCT05899608

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3).

TRIAL NUMBER - NCT05450692

A Phase III, Open-label, Randomized, Multicenter Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

TRIAL NUMBER - NCT05909904

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

TRIAL NUMBER - NCT05687266

Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR).

TRIAL NUMBER - NCT03526835

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors.

TRIAL NUMBER - THOR-1

A study to collect clinical as well as genomic data on lung cancer patients in order to improve our understanding of thoracic malignancies in our community as well as disparities that may affect patient access to treatment.

TRIAL NUMBER - NCT05211895

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8).

TRIAL NUMBER - NCT05091567

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab.